Will chymase inhibitors be the next major development for the treatment of cardiovascular disorders?

Author： Doggrell Sheila A Wanstall Janet C

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.8, 2003-08, pp. : 1429-1432

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chymase Inhibitors

Current Pharmaceutical Design, Vol. 19, Iss. 17, 2013-05 ,pp. : 3065-3071

Bentham Science Publishers

Access to resources Recommend Favorite

Development of aldose reductase inhibitors for the treatment of inflammatory disorders

By Chatzopoulou Maria Pegklidou Kyriaki Papastavrou Nikolaos Demopoulos Vassilis J

Expert Opinion on Drug Discovery, Vol. 8, Iss. 11, 2013-11 ,pp. : 1365-1380

Informa Healthcare

Access to resources Recommend Favorite

Targets of chymase inhibitors

By Takai Shinji Jin Denan Miyazaki Mizuo

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 4, 2011-04 ,pp. : 519-527

Informa Healthcare

Access to resources Recommend Favorite

Non-peptidic chymase inhibitors

By Aoyama Yasunori

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 9, 2001-09 ,pp. : 1423-1428

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic Potential of Renin Inhibitors in the Management of Cardiovascular Disorders

By Stanton A.

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 6, 2003-01 ,pp. : 389-394

Adis International

Access to resources Recommend Favorite